Successful treatment with azacitidine in VEXAS syndrome with prominent myofasciitis
Rheumatology (Oxford)
.
2022 May 5;61(5):e117-e119.
doi: 10.1093/rheumatology/keab866.
Authors
Isabell Cordts
1
,
Judith S Hecker
2
,
Darja Gauck
3
,
Joohyun Park
3
,
Johanna Härtl
1
,
Roman Günthner
4
,
Ariane Hammitzsch
4
,
Benedikt Schoser
5
,
Dietrich Abeck
6
,
Katharina S Götze
2
,
Tobias B Haack
3
7
,
Marcus Deschauer
1
,
Philipp Moog
4
8
,
Bernhard Hemmer
1
9
Affiliations
1
Department of Neurology.
2
Department of Medicine III, Klinikum Rechts der Isar, Technical University Munich, Munich.
3
Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen.
4
Department of Nephrology, Technische Universität München, Klinikum Rechts der Isar.
5
Department of Neurology, Friedrich-Baur-Institute, Ludwig-Maximilians University.
6
Hautzentrum Nymphenburg, Munich.
7
Centre for Rare Diseases, University of Tübingen, Tübingen.
8
MVZ für Rheumatologie Dr. Martin Welcker, Planegg.
9
Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.
PMID:
34894213
DOI:
10.1093/rheumatology/keab866
No abstract available
MeSH terms
Azacitidine / therapeutic use
Humans
Myelodysplastic Syndromes*
Myositis* / drug therapy
Ubiquitin-Activating Enzymes
Substances
Ubiquitin-Activating Enzymes
Azacitidine